life science investing Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies
life science investing Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635
life science investing Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
